This potential TB treatment regimen was identified by its impressive performance in vitro in TB Alliance’s preclinical regimen identification program. This regimen showed the potential to shorten TB treatment to less than 4 months for patients sensitive to the therapies in the regimen. This is an oral regimen, removing the need for injectables as part of MDR-TB treatment and also projecting to be markedly less expensive than current MDR-TB therapy. This regimen also showed promise to be able to be administered alongside common ARV treatments, thereby improving treatment options for patients co-infected with TB and HIV. Additionally, this regimen can be administered in a fixed dose for all patients, and will therefore be simpler for health systems to deliver and patients to use.